Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Thrombophilia D019851 6 associated lipids
Endotoxemia D019446 27 associated lipids
Pancreatitis, Acute Necrotizing D019283 18 associated lipids
Atrial Premature Complexes D018880 1 associated lipids
Sepsis D018805 11 associated lipids
Systemic Inflammatory Response Syndrome D018746 4 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Osteoblastoma D018215 1 associated lipids
Aortic Aneurysm, Abdominal D017544 5 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Chakroun T et al. Screening for aspirin resistance in stable coronary artery patients by three different tests. 2007 Thromb. Res. pmid:17553552
Pucsok JM et al. Effect of exercise on levels of cyclo-oxygenase mediators in exhaled breath condensate in elite athletes. 2007 J Sports Med Phys Fitness pmid:17557063
Hohlfeld T et al. Variable platelet response to aspirin in patients with ischemic stroke. 2007 Cerebrovasc. Dis. pmid:17519543
Allais G et al. Naproxen sodium in short-term prophylaxis of pure menstrual migraine: pathophysiological and clinical considerations. 2007 Neurol. Sci. pmid:17508177
Wong PC et al. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits. 2007 J. Cardiovasc. Pharmacol. pmid:17513951
Hsiao G et al. Characterization of a novel and potent collagen antagonist, caffeic acid phenethyl ester, in human platelets: in vitro and in vivo studies. 2007 Cardiovasc. Res. pmid:17560560
Basselin M et al. Flurbiprofen, a cyclooxygenase inhibitor, reduces the brain arachidonic acid signal in response to the cholinergic muscarinic agonist, arecoline, in awake rats. 2007 Neurochem. Res. pmid:17562170
Aras-Lopéz R et al. Dexamethasone decreases contraction to electrical field stimulation in mesenteric arteries from spontaneously hypertensive rats through decreases in thromboxane A2 release. 2007 J. Pharmacol. Exp. Ther. pmid:17562850
Gurbel PA et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. 2007 Circulation pmid:17562955
Tu CT et al. Antifibrotic activity of rofecoxib in vivo is associated with reduced portal hypertension in rats with carbon tetrachloride-induced liver injury. 2007 J. Gastroenterol. Hepatol. pmid:17565644
Sun LQ et al. [Relationship between syndrome differentiation of traditional Chinese medicine and vascular endothelial function in patients with diabetic arterial occlusion of lower extremities]. 2007 Zhong Xi Yi Jie He Xue Bao pmid:17997934
Marvin CC et al. Synthesis of thromboxane B2 via ketalization/ring-closing metathesis. 2007 Org. Lett. pmid:18047355
Wang Z et al. Changes of vasoactive polypeptides during postoperative hypertensive crisis in patients with hypertensive intracerebral hemorrhage. 2007 Chin. Med. J. pmid:18167188
DiChiara J et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. 2007 Diabetes pmid:17848625
Shemesh E et al. Symptoms of posttraumatic stress disorder in patients who have had a myocardial infarction. 2006 May-Jun Psychosomatics pmid:16684940
Tuominen OM et al. Effects of bisphosphonates on prostaglandin E2 and thromboxane B2 production in human whole blood and monocytes stimulated by lipopolysaccharide and A23187. 2006 Jul-Aug Methods Find Exp Clin Pharmacol pmid:16894405
Wang LH et al. Effect of heparin on activation of platelet function in patients during radiofrequency catheter ablation. 2006 Jan-Feb Clin. Exp. Pharmacol. Physiol. pmid:16445701
Wynn RL and Cook J Does ibuprofen block the cardioprotective effects of aspirin in dental patients? 2006 Jan-Feb Gen Dent pmid:16494111
Sciulli MG et al. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease. 2006 Clin. Pharmacol. Ther. pmid:16890573
Shi T et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. 2006 Arthritis Rheum. pmid:16868978
Ramamurthy S et al. Characterization of thromboxane A2 receptor signaling in developing rat oligodendrocytes: nuclear receptor localization and stimulation of myelin basic protein expression. 2006 J. Neurosci. Res. pmid:16998891
Zhou Y et al. Increased expression of cyclooxygenase-2 mediates enhanced contraction to endothelin ETA receptor stimulation in endothelial nitric oxide synthase knockout mice. 2006 Circ. Res. pmid:16645140
Karkabounas S et al. Anticarcinogenic and antiplatelet effects of carvacrol. 2006 Exp. Oncol. pmid:16837902
Wilder-Smith CH et al. Dose-effect comparisons of the CINOD AZD3582 and naproxen on upper gastrointestinal tract mucosal injury in healthy subjects. 2006 Scand. J. Gastroenterol. pmid:16497612
Brenneis C et al. Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition. 2006 FASEB J. pmid:16816110
Baltzer WI et al. Measurement of urinary 11-dehydro-thromboxane B2 excretion in dogs with gastric dilatation-volvulus. 2006 Am. J. Vet. Res. pmid:16426215
Chiu HF et al. Mechanisms involved in the antiplatelet effect of C-phycocyanin. 2006 Br. J. Nutr. pmid:16469164
Rossoni G et al. Nitric oxide and prostacyclin pathways: an integrated mechanism that limits myocardial infarction progression in anaesthetized rats. 2006 Pharmacol. Res. pmid:16488624
Lepäntalo A et al. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. 2006 Thromb. Haemost. pmid:16493486
Kurosawa S et al. Effects of ulinastatin on pulmonary artery pressure during abdominal aortic aneurysmectomy. 2006 J Clin Anesth pmid:16517327
Flipo RM [Are the NSAIDs able to compromising the cardio-preventive efficacy of aspirin?]. 2006 Presse Med pmid:17078596
Ibrahim S et al. Transfer of very low density lipoprotein-associated phospholipids to activated human platelets. 2006 J. Lipid Res. pmid:16293890
Fontana P et al. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. 2006 J. Thromb. Haemost. pmid:16634751
Markuszewski L et al. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin? 2006 Basic Clin. Pharmacol. Toxicol. pmid:16635110
Cheung PY et al. Platelet dysfunction in asphyxiated newborn piglets resuscitated with 21% and 100% oxygen. 2006 Pediatr. Res. pmid:16627873
Laleman W et al. A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited. 2006 Eur. J. Clin. Invest. pmid:16620286
Zhao Y et al. Effect of a Chinese herbal formula, Shi-Bi-Lin, on an experimental model of allergic rhinitis. 2006 Ann. Allergy Asthma Immunol. pmid:16802773
Lee KS et al. Antiplatelet activity of [5-(2-methoxy-5-chlorophenyl)furan-2-ylcarbonyl]guanidine (KR-32570), a novel sodium/hydrogen exchanger-1 and its mechanism of action. 2006 Arch. Pharm. Res. pmid:16756082
Peck OM et al. The phosphatidylinositol 3 kinase pathway regulates tolerance to lipopolysaccharide and priming responses to Staphylococcus aureus and lipopolysaccharide. 2006 Shock pmid:16783195
Frelinger AL et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. 2006 Circulation pmid:16785341
Cox D et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. 2006 Stroke pmid:16794200
Munsterhjelm E et al. Influence on platelet aggregation of i.v. parecoxib and acetaminophen in healthy volunteers. 2006 Br J Anaesth pmid:16698862
Vranic II et al. Adenosine cardioprotection study in clinical setting of paroxysmal supraventricular tachycardia. 2006 Prostaglandins Leukot. Essent. Fatty Acids pmid:16682179
Zhang JY et al. [Study on therapeutic effects of series of muskone on myocardial infarction canines]. 2006 Zhongguo Zhong Yao Za Zhi pmid:17225541
Basili S et al. Insulin resistance as a determinant of platelet activation in obese women. 2006 J. Am. Coll. Cardiol. pmid:17174194
Hrushka NH et al. [Effect of thromboxane B2 on morphological features of apoptosis in cultured rat hepatocytes exposed to hepatotropic substances]. 2006 Fiziol Zh pmid:17176837
Niemi TT et al. The effect of N-acetylcysteine on blood coagulation and platelet function in patients undergoing open repair of abdominal aortic aneurysm. 2006 Blood Coagul. Fibrinolysis pmid:16607076
Chiang N and Serhan CN New mechanism for an old drug: aspirin triggers anti-inflammatory lipid mediators with gender implications. 2006 Compr Ther pmid:17435267
Chiang N et al. Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: a randomized human trial. 2006 Arterioscler. Thromb. Vasc. Biol. pmid:16293793
Wolfram RM et al. Salivary isoprostanes indicate increased oxidation injury in periodontitis with additional tobacco abuse. 2006 Biofactors pmid:17264390